PALVELLA THERAPEUTICS INC (PVLA)
Health Care · Biotechnology · NASDAQ
A biopharmaceutical company advancing a pipeline of proprietary therapies for rare skin diseases and vascular malformations.
What PALVELLA THERAPEUTICS INC does
Palvella Therapeutics is a biopharmaceutical company focused on developing therapies for rare skin diseases and vascular malformation indications. The company utilizes a proprietary drug development platform to advance a pipeline of product candidates, including QTORIN™ rapamycin and QTORIN™ pitavastatin.
Themes: Rare skin diseases, Vascular malformations, Dermatology drug development
Fundamentals
- Price$131.34 as of 2026-10-08 close
- Market cap$1.9B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+75.5% 2025-10-08 close $74.85 → 2026-10-08 close $131.34
- P/En/a negative earnings
- Net margin+43.7% FY2023, SEC XBRL
- ROE-149.1% FY2025, SEC XBRL
- Debt / equity0.10 as of 2026-09-02
- Revenue growth (YoY)-97.2% as of 2026-09-02
- Revenue CAGR (3y)+13.4% SEC XBRL
- Beta0.93 as of 2026-09-02
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How PVLA compares in its sector
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
PVLA is not currently in any published Top 10 list. Its scores are below.
Top 10 score
35.1 #1300 of 1,388 scored · #142 of 154 in Health Care
Trend 82nd (a "golden cross" — its 50-day average is above its 200-day) and financial health 44th (debt to equity 0.1, free cash flow margin -32.4%); weakest is profitability (3rd, return on equity -149.1%, operating margin -27.7%).
Scores as of 29 Sep 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4. PVLA was not in the scored universe at the latest run on 8 Oct 2026, so these scores are its last ones.
How PALVELLA THERAPEUTICS INC looks technically
PALVELLA THERAPEUTICS INC (PVLA) is trading 6.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 516 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 18.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 6.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +6.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $147.85 | $147.85 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $123.63 | $123.63 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 160.84. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 516 trading days ago — a "golden cross", a bullish long-term signal | 516 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend) | 24.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 35.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($124.50 to $160.84) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 18.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $161.38 | $161.38 |
|---|---|---|
| From the 52-week high | it is 18.6% below its 52-week high (its highest price of the past year) | -18.6% |
| Above the 52-week low | it is 132.3% above its 52-week low (its lowest price of the past year) | +132.3% |
| Below the 52-week high | it is 18.6% below its highest point of the past year | 18.6% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $780.00 (set on 2018-02-13) | $780.00 |
| Given back of the 52-week move | over the past year its closes ranged ($57.69 to $158.13), and it has given back roughly a quarter of its rise from last year’s low — 27% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $92.84 to $96.06. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 26.7% |
| From the all-time high | it is 83.2% below its all-time high | -83.2% |
| Nearest price level | it is trading 2.5% below a resistance level at $134.61 — a price it turned at four times since 2026-03-31, most recently on 2026-08-24. Since 2024-10-08 it has 8 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.5% |
| All-time low | its lowest closing price on record is $6.20 (set on 2024-07-12) | $6.20 |
| Above the all-time low | it is 2018.4% above its all-time low | +2,018% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 75% of it) | 75th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.93 between its high and its low — about 5.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.93 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $124.15 and $161.72 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $124.15 – $142.94 – $161.72 |
| Typical daily range (% of price) | its price moves about 5.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.3% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges above its 200-day average price (6.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.94× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-09-17 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 14 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +2.61% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 14.8 percentage points (the stock lost 13.8% while the market gained 1.0%) | -14.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.4 percentage points (the stock lost 9.5% while the market gained 3.8%) | -13.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 7.9 percentage points (the stock gained 9.6% while the market gained 17.5%) | -7.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 60.5 percentage points (the stock gained 75.5% while the market gained 15.0%) | +60.5% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.5% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -3.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $124.57 — a volume-weighted average of daily closes over 183 sessions, not a true tick-by-tick VWAP. | +5.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $147.42 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -10.9% |
Double top, bearish — broke down · entry $142.04 · 43 sessions in
Ascending triangle, either side — broke down · the lower entry $152.84 · 83 sessions in
Price levels it has turned at before
PVLA last closed at $131.34 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $134.61 | Resistance | 2.5% above the last close | turned there four times · 2026-03-31 to 2026-08-24 |
| $121.07 | Support | 7.8% below the last close | turned there twice · 2026-04-16 to 2026-07-21 |
| $144.84 | Resistance | 10.3% above the last close | turned there twice · 2026-03-10 to 2026-09-09 |
| $108.99 | Support | 17.0% below the last close | turned there twice · 2026-03-20 to 2026-03-30 |
| $106.49 | Support | 18.9% below the last close | turned there twice · 2025-11-28 to 2026-01-15 |
| $159.84 | Resistance | 21.7% above the last close | turned there six times · 2026-06-30 to 2026-09-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $160.84.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · lagging the market · Printed a hammer candle after a decline · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 15 analysts
- Mean price target$230.53 range $205.00 – $270.00; median $232.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PVLA
- Consensus EPS estimate-$1.74 next reporting period, as of 2026-10-04
- Estimate change, 30 days-$0.0075 from -$1.74, on 2026-08-30, 35-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on clinical trial outcomes to demonstrate safety and efficacy for FDA approval.","Need for additional capital to fund research, development, and commercialization activities.","Significant uncertainty regarding regulatory approval timelines for lead product candidates."]
What changed in the latest 10-Q
AI-assisted comparison of PVLA's 10-Q filed 2026-05-07 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 2025 Form 10-K filed March 31, 2026 (newer filing) vs. 2024 Form 10-K filed March 31, 2025 (older filing)
- Added overview statement: vision includes vascular malformations specifically
- Added: 'vascular malformations' to opening overview description
- Added: 'and vascular malformations for which there are no FDA-approved therapies' in overview
- Added: description of treatment paradigm for individuals with vascular malformations
- Added: QTORIN rapamycin is 'currently in clinical development for...cutaneous venous malformations'
- Added: 'We are also expanding our QTORIN rapamycin development program into clinically significant angiokeratomas'
- Added: Introduction of QTORIN pitavastatin for DSAP treatment
- Added: 'We announced positive topline results for two clinical trials' describing SELVA and TOIVA outcomes
- Added: January 2026 FDA Preliminary Breakthrough Therapy Designation Advice meeting for cutaneous VM program
- Added: February 2026 positive topline results announcement for SELVA
- Added: March 2026 pre-NDA meeting request submitted to FDA, subsequently granted
- Added: February 2026 FDA feedback on Phase 2 angiokeratomas study design
- Added: April 2026 first patient dosing in Phase 2 LOTU trial for angiokeratomas
- Added: March 2026 'BEYOND mLM' disease awareness campaign and website launch
- Added: 2026 three senior leadership appointments (Vimal Patel, Jennifer McDonough, Kent Taylor)
- Added: April 2026 appointment of John D. Doux to Board of Directors
- Added: Overview statement for QTORIN rapamycin includes 'clinically significant angiokeratomas' as indication
- Added: 'If approved, we believe QTORIN rapamycin has the potential to become the first line therapy and the standard of care'
- Added: Microcystic LM estimated patient population 'more than 30,000 diagnosed patients in the United States'
- Added: Reference to 'somatic activating mutations in PIK3CA' (vs. 'PIK3CA gene' in older)
- Removed:
- Removed: reference to 2024 Form 10-K
- Removed: 'We currently have two ongoing clinical trials' (replaced with 'We announced positive topline results')
- Removed: May 2025 FDA grant proceeds announcement ($0.5 million)
- Removed: June 2025 USPTO patent grant (No. 12,329,748)
- Removed: June 2025 SELVA enrollment completion announcement
- Removed: September 2025 TOIVA enrollment completion announcement
- Removed: September 2025 angiokeratomas expansion announcement
- Removed: November 2025 QTORIN pitavastatin announcement
- Removed: 'We currently have two ongoing clinical trials' phrasing
- Removed: 'additional preclinical research programs' (replaced with 'preclinical research programs')
- Removed: Description of lymphorrhea as 'the persistent discharge of internal lymph fluid from disrupted lymphatic vessels'
- Removed: Description of acute cellulitis as 'a bacterial infection of the skin underlying tissues'
- Removed: 'Microcystic LMs is a rare' (changed to 'Microcystic LM is a serious')
- Removed: 'the PIK3CA gene' phrasing
- Removed: 'There are currently no FDA-approved treatments for the estimated more than 30,000 individuals in the U.S. with microcystic LMs'
- Removed: 'In the third quarter of 2024, we initiated SELVA'
- Removed: '24-week' duration reference for SELVA trial
- Removed: 'administered topically once daily' from SELVA trial description
- Removed: Primary endpoint full description including 'change from baseline in the overall microcystic LM Investigator Global Assessment, a 7-point clinician rated changes scale, at week 24'
- Removed: 'In the first quarter of 2025, we announced the expansion of our SELVA trial to include patients ages 3 to 5 years old'
- Removed: 'Previously, trial participants were required to be at least 6 years old'
- Removed: 'In the second quarter of 2025 we completed enrollment'
- Removed: 'Following an 8-week baseline period and 24-week evaluation, eligible participants may continue treatment in an open-label extension study'
- Removed: 'The open-label extension study also remains open to enrolling new subjects aged three to five years'
- Removed: 'We expect to report top-line data for the Phase 3 study in the first quarter of 2026'
- Removed: 'We have received Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA for QTORIN rapamycin for the treatment of microcystic LMs'
- Removed: 'Orphan Drug Designation has also been granted by the European Medicines Agency'
- Removed: 'In addition, we have been awarded an FDA Orphan Products Clinical Trials Grant for up to $2.6 million supporting the SELVA Phase 3 study'
- Removed: 'In May 2025, we received initial proceeds of $0.5 million from the FDA under such grant'
- Reworded:
- Changed overview opening from 'for developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare skin diseases' to include 'and vascular malformations'
- Changed 'We intend to leverage' to 'We intend to leverage our versatile QTORIN platform to minimize the challenges and timelines typically associated with generating novel topical product candidates'
- Changed QTORIN rapamycin development status from 'currently in clinical development for microcystic LMs and cutaneous VMs' to explicitly separate into ongoing trials and expansion into angiokeratomas
- Changed 'We currently have two ongoing clinical trials' to 'We announced positive topline results for two clinical trials'
- Changed QTORIN rapamycin overview from 'for the treatment of microcystic LMs, cutaneous VMs, and other mTOR-driven skin diseases' to include 'clinically significant angiokeratomas'
- Changed standard of care language from 'the standard of care in each of these diseases' to 'the first line therapy and the standard of care in each of these diseases'
- Changed microcystic LM description from 'rare, chronically debilitating' to 'serious, chronically debilitating'
- Changed lymphorrhea description from full explanatory text to abbreviated 'lymphorrhea'
- Changed acute cellulitis description from full explanatory text to abbreviated 'acute cellulitis'
- Changed 'PIK3CA gene' to 'PIK3CA' without 'gene' designation
- Changed structure of SELVA trial narrative from chronological explanation with enrollment completion dates to reporting of completed trial with topline results
- Notes:
- The newer filing's MD&A section appears truncated at 'The primary endpoint, the mLM-IGA, is a 7-point clinician-assessed dynamic scale measuring change in disea', making full comparison of that section impossible
- Recent Developments section in older filing contained May-November 2025 updates; newer filing contains January-April 2026 updates, representing a natural progression of time rather than retroactive changes
- Older filing discusses trials as 'ongoing'; newer filing discusses same trials as 'completed' with 'positive topline results', reflecting advancement of clinical programs
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 22 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 12 sells ($5M) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 22 sells ($6M) — 3 selling insiders
- Last 180 days · read to 2026-10-040 buys · 28 sells ($7M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-16. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PVLA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PVLA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,934,080
- Reported value $295,566,030
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PVLA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PVLA had 2,325,699 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
PVLA had 16.1% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.82 days to cover at the same settlement.
- Reported short interest (shares) 2,325,699
- Short interest (% of shares outstanding) 16.1%
- Prior settlement (shares) 2,291,288
- Reported change 1.5%
- Days to cover (reported) 12.82
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Frequently asked questions
What does PALVELLA THERAPEUTICS INC (PVLA) do?
Palvella Therapeutics is a biopharmaceutical company focused on developing therapies for rare skin diseases and vascular malformation indications. The company utilizes a proprietary drug development platform to advance a pipeline of product candidates, including QTORIN™ rapamycin and QTORIN™ pitavastatin.
What sector is PALVELLA THERAPEUTICS INC (PVLA) in?
PALVELLA THERAPEUTICS INC (PVLA) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is PALVELLA THERAPEUTICS INC (PVLA) overbought or oversold right now?
PALVELLA THERAPEUTICS INC (PVLA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PVLA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.